Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)
British Journal of Dermatology2017Vol. 178(3), pp. 674–681
Citations Over TimeTop 10% of 2017 papers
Kim Papp, C. Leonardi, Andrew Blauvelt, Kristian Reich, N.J. Korman, Mamitaro Ohtsuki, C. Paul, Susan Ball, Gregory S. Cameron, J. Erickson, L. Zhang, Lotus Mallbris, C.E.M. Griffiths
Abstract
Ixekizumab therapy at both dosing regimens demonstrated rapid onset and superior efficacy to placebo and etanercept, with IXE Q2W providing better outcomes than IXE Q4W during the first 12 weeks of treatment.
Related Papers
- → Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial(2008)178 cited
- → Efficacy of etanercept in an integrated multistudy database of patients with psoriasis(2006)111 cited
- → Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3(2018)30 cited
- → Low‐dose etanercept therapy in moderate to severe psoriasis in Korean(2008)21 cited
- → Long-term, continuous dosing of etanercept in patients with plaque psoriasis(2011)1 cited